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Abstract
Background: We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal
cancer treatment.
Methods: We analyzed patient surveys and medical records for a population-based cohort with metastatic
colorectal cancer treated in multiple regions and health systems in the United States (US). Eligible patients were
diagnosed with metastatic colorectal cancer and initiated first-line chemotherapy after US Food & Drug
Administration (FDA) bevacizumab approval in February 2004. First-line bevacizumab therapy was defined as
receiving bevacizumab within 8 weeks of starting chemotherapy for metastatic colorectal cancer. We evaluated
factors associated with first-line bevacizumab treatment using logistic regression.
Results: Among 355 patients, 31% received first-line bevacizumab in the two years after FDA approval, including
26% of men, 41% of women, and 16% of those ≥ 75 years. Use rose sharply within 6 months after FDA approval,
then plateaued. 20% of patients received bevacizumab in combination with irinotecan; 53% received it with
oxaliplatin. Men were less likely than women to receive bevacizumab (adjusted OR 0.55; 95% CI 0.32-0.93; p =
0.026). Patients ≥ 75 years were less likely to receive bevacizumab than patients < 55 years (adjusted OR 0.13; 95%
CI 0.04-0.46; p = 0.001).
Conclusions: One-third of eligible metastatic colorectal cancer patients received first-line bevacizumab shortly after
FDA approval. Most patients did not receive bevacizumab as part of the regimen used in the pivotal study leading
to FDA approval.
Background
Bevacizumab, a monoclonal antibody against vascular
endothelial growth factor, was the first biologic agent
shown to improve median overall survival (by 4.7
months) in patients with metastatic colorectal cancer,
when given with cytotoxic chemotherapy [1]. Results of
the first phase III study demonstrating this benefit were
released publically in June, 2003, and published in June,
2004. The United States (US) Food and Drug Adminis-
tration (FDA) approved bevacizumab for first-line treat-
ment of metastatic colorectal cancer in February, 2004.
The drug was approved by the European Union a year
later in January, 2005. Although effective in prolonging
survival, bevacizumab is expensive,[2] can cause hyper-
tension, cardiovascular events, and in rare instances,
severe hemorrhage or gastrointestinal tract perforation
[1,3].
Little is known about the early uptake of new biologic
therapies such as bevacizumab for advanced cancer. Spe-
cifically, 1) what is the initial dissemination pattern of
biologic agents?; and 2) how do clinicians interpret clini-
cal trial results for biologic agents, especially since selec-
tive trial eligibility mightn o tr e p r e s e n tt h eb r o a d
spectrum of patients treated in the community setting?
[4] Registry studies for bevacizumab have examined post-
marketing safety and efficacy, but these studies cannot
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received bevacizumab [5,6].
Answering these questions is critically important in
light of recent regulatory decisions related to bevacizu-
mab. At the end of 2010, the FDA recommended
removing bevacizumab’s breast cancer indication due to
lack of survival benefit; the European Medicines Agency
has maintained its indication but only in combination
with paclitaxel. In light of the high drug cost, we must
understand how novel agents are used in standard care
since in certain instances, rapid dissemination occurs
despite lack of long-term, phase IV data.
We used data from the Cancer Care Outcomes
Research and Surveillance (CanCORS) Consortium, a
US population- and healthcare systems-based study of
newly-diagnosed patients with colorectal cancer, to
describe the uptake of bevacizumab and to identify fac-
tors associated with its use. Comprehensive medical
record abstraction enabled us to evaluate bevacizumab
use in relationship to comorbidity and other patient
characteristics not typically available in cancer registry
data [7]. Thus, we were able to examine dissemination
of this new therapy in a broad range of community
settings.
Methods
Cancer Care Outcomes Research and Surveillance
Consortium
CanCORS is a prospective, observational, population- and
healthcare systems-based cohort study designed to deter-
mine how characteristics of cancer patients, providers, and
health care organizations influence treatments and out-
comes in newly diagnosed lung or colorectal cancer
patients [8]. The full CanCORS cohort appears representa-
tive of the US Surveillance, Epidemiology, and End Results
(SEER) registry sample: CanCORS participants did not dif-
fer from their corresponding SEER population by more
than 8 percentage points in any important demographic
characteristics such as gender, race, age, and stage [9].
Patients with colorectal cancer were nationally enrolled
from geographically diverse populations and health care
systems, including five integrated health care systems in
the NCI-funded Cancer Research Network, and fifteen
Veterans Administration Hospitals [8]. Primary data were
collected from patient surveys and medical records.
Human subject committees approved the study protocol
at each participating site.
Patients
Eligible patients were at least 21 years old and were iden-
tified within 3 months of diagnosis of colorectal cancer.
Three thousand six hundred sixty-four incident cases of
colorectal cancer (Figure 1) were enrolled in the Can-
CORS cohort between September, 2003 to January, 2006,
including 742 patients (20%) with advanced colorectal
cancer (677 with stage IV cancer at diagnosis, and 65
with a metastatic or regional recurrence within the 15-
month post-diagnosis follow-up period of the study). Of
note, this stage distribution (20% with advanced cancer)
is consistent with that seen in the SEER registry, where
patients with advanced colorectal cancer comprise 19%
of all patients [10]. Of the 742 patients in our cohort with
stage IV or recurrent disease, 355 initiated first-line treat-
ment after the bevacizumab approval date in February,
2004 and were included in this analysis. Hence, the sub-
cohort of interest for this analysis began treatment from
March, 2004-January, 2006. All patients or their surro-
gates provided informed consent at enrollment. Recruit-
ment materials and patient surveys were translated into
Spanish and Chinese.
Data Collection
Medical records data were abstracted by trained abstrac-
tors at each of the data-collection sites. The time window
for records abstraction was three months before diagnosis
to fifteen months after diagnosis. Data abstractors had
professional experience as cancer registrars or nurses and
underwent an intensive four-day training course on data
collection processes and standards in CanCORS. Quality
assurance was monitored by completion of up to six gold-
standard reference chart abstractions per abstractor.
Presence of comorbid illness was collected as part of the
medical record abstraction. The degree of comorbidity
was scored using the Adult Comorbidity Evaluation 27
(ACE-27), a 27-item index developed to provide prognos-
tic information for cancer patients [11].
Primary data were collected from patients via computer-
assisted telephone interviews 4-7 months after diagnosis.
For patients who had died or were too ill to be interviewed,
a surrogate (relative or household member) familiar with
their cancer care was interviewed. The surveys (available at
http://www.cancors.org/public) assessed patients’ sociode-
mographic characteristics (age, race/ethnicity, annual
income), insurance coverage, comorbid conditions, and
beliefs about cancer care (see Additional file 1) [12].
Surveys were the primary source of insurance informa-
tion; medical records provided a secondary source. We
categorized patients by whether or not they received care
in an integrated health system, defined as one of the 5 par-
ticipating health maintenance organizations, a California
Kaiser Permanente plan, or one of the participating Veter-
ans Administration hospitals [8]. Patients were also classi-
fied by US region (South, including sites in Alabama,
Mississippi, Tennessee, Texas, Georgia; Atlantic, including
sites in Massachusetts, Maryland, New York, and North
Carolina; and West/Midwest, including sites in Arizona,
California, Oregon, Washingto n ,I o w a ,I l l i n o i s ,I n d i a n a ,
Michigan, Minneapolis, Indiana).
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receipt of bevacizumab within 8 weeks of starting any
chemotherapy for stage IV or recurrent colorectal can-
cer. For instance, a patient who began metastatic color-
ectal cancer treatment with cytotoxic chemotherapy,
then had bevacizumab addedt ot h er e g i m e n6w e e k s
later was categorized as receiving first-line bevacizumab.
Rates of first-line bevacizumab use pertain to the period
from March, 2004 (the month after FDA approval) to
January, 2006. To evaluate the relationship between dif-
fusion of bevacizumab and calendar time since FDA
approval, we analyzed quarterly usage. Since CanCORS
participants were enrolled as a fixed cohort, and the rate
of enrollment in CanCORS did not remain constant
over the study period, the denominator of eligible
patients per quarter (any patients starting any first-line
chemotherapy) decreased over time.
The FDA approved bevacizumab based on the results of
the pivotal phase III study where bevacizumab was deliv-
ered in combination with 5-fluorouracil and irinotecan;[1]
however, approval was for use “with intravenous 5-fluor-
ouracil-based chemotherapy,” without specifying use of
additional agents, such as irinotecan or oxaliplatin [13]. To
determine how strictly practitioners interpreted trial data
and FDA indication, we described which other drugs were
delivered in combination with first-line bevacizumab.
Statistical Analyses
We calculated descriptive statistics summarizing sociode-
mographic, comorbidity data, and survey-based patient
3664 All CRC patients with completed abstractions
742 mCRC
2922 non-mCRC
571 received chemotherapy
171 untreated
537 had treatment date available
34 no treatment date available
380 first chemo 3/2004 or later
157 first chemo before 3/2004
151 received bevacizumab 204 did not receive 
bevacizumab
110 received 1st-line 
bevacizumab
41 did not receive 1st-
line bevacizumab
25 without patient survey
355 with patient survey
4715 CRC patients surveyed
1051 with incomplete records or subsequently ineligible
7843 CRC patients contacted
3128 not surveyed
10242 CRC patients sampled
2399 unable to contact
Figure 1 CONSORT-like diagram for the analytic cohort obtained from the overall CanCORS cohort*. *The dotted line encases patients
who were considered for this analysis. First-line therapy with bevacizumab was defined as receipt of bevacizumab within 8 weeks of starting
any chemotherapy for stage IV or recurrent colorectal cancer (mCRC).
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with treatment using logistic regression. Results of multi-
variable modeling are presented as odds ratios (OR), two-
sided p-values, and 95% confidence intervals (with asso-
ciated confidence interval plots) [14]. Variables were
selected for inclusion in multivariable models using a
combination of statistical selection criteria (e.g., sufficient
variation across values of the outcome, p < 0.25 in unad-
justed analyses) and a priori scientific interest (race/eth-
nicity and comorbidity). Multiple imputation was used to
address item nonresponse for survey-based variables and
was performed centrally by the CanCORS Statistical
Coordinating Center [15]. The presented results from
multivariable models incorporate formal imputation
adjustments [16]. Data analysis was conducted at the
Durham Veterans Administration Medical Center, the
coordinating site for Veterans Administration hospitals
participating in CanCORS. This analysis used CanCORS
core data (version 1.9), medical record data (version 1.9)
and patient survey data (version 1.8). Statistical analyses
were performed using SAS for Windows Version 9.2
(SAS Institute, Cary, NC).
Results
Cohort characteristics
Three hundred fifty-five patients met inclusion criteria
for this analysis (Figure 1). Their characteristics are
detailed in Table 1; 66% percent were male, 18% were ≥
75 years old, and 62% were white. Seventy-three percent
had no or mild comorbidity (ACE-27 score of 0-1). Since
the most common contraindications to bevacizumab are
related to cardiovascular disease, we described incidence
of cardiovascular disease based on data from the ACE-27
(Table 1). Forty-nine percent of patients had at least one
cardiovascular risk factor. Thirty-six percent had private
insurance, 13% had public insurance, 27% had Medicare
plus supplemental insurance, and 19% had Veterans
Administration healthcare. Of those with only public
insurance, 64% had Medicare, 62% had Medicaid, and
33% had both.
Dissemination of bevacizumab after FDA approval
Of the 355 patients in this cohort eligible to receive bev-
acizumab from March, 2004 (after FDA approval) to
January, 2006, 31% received the drug as a component of
their first-line systemic treatment for stage IV or recur-
rent disease (Figure 1). Figure 2 displays the quarterly
use of bevacizumab 9 months before FDA approval to
12 months after FDA approval of bevacizumab. Only
20% of patients starting first line therapy for metastatic
colorectal cancer received first-line bevacizumab in
March 2004, the month after FDA approval. In the year
following approval, the highest percentage of use was
seen during June-August 2004, specifically in July 2004
(48%), a month after publication of the pivotal phase III
study which reported the drug’s efficacy [1].
Drugs used in combination with bevacizumab
The FDA approved bevacizumab for use with intrave-
nous 5-fluorouracil-based chemotherapy. Seventy-five
Table 1 Baseline characteristics of study cohort
Characteristic* All patients (n = 355)
N%
Age in years
<5 5 9 2 2 6
55-64 106 30
65-74 94 27
≥ 75 63 18
ACE-27 Comorbidity Index (score)
None (0) 120 34
Mild (1) 140 39
Moderate (2) 51 14
Severe (3) 44 12
Race
Non-white 134 38
White 221 62
Gender
Female 120 34
Male 235 66
Insurance
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Missing 19 5
Public 45 13
Medicare + Supplemental 96 27
Veterans Administration 67 19
Private 128 36
Geographic region
West/Midwest 178 50
South 91 26
Atlantic 86 24
Health system
Fee-for-Service 212 60
Integrated health system 143 40
Annual household income
Missing 66 19
< $20,000/year 100 28
≥ $20,000/year 189 53
Diagnosis of metastatic disease
Recurrence 58 16
Stage IV at diagnosis 297 84
Primary tumor site
Missing 5 1
Colon 258 73
Rectum 76 21
Colorectal 16 5
Receipt of surgery within 4 weeks of chemotherapy
No qualifying surgery within 4 weeks 321 90
Qualifying surgery within 4 weeks 34 10
Presence of any of following 5 cardiovascular risks
No risk factor grade > 0 181 51
Presence of ≥ 1 risk factor grade > 0 174 49
Hypertension
Grade 0 203 57
Grade > 0 152 43
Angina/coronary artery disease
Grade 0 307 87
Grade > 0 48 14
Venous disease including venous thrombosis
Grade 0 346 98
Grade > 0 9 3
Peripheral artery disease
Grade 0 345 97
Grade > 0 10 3
Congestive heart failure
Grade 0 342 96
Grade > 0 13 4
*Only three patients had missing insurance data after imputation. The composition of health systems in the health system categorization of fee-for-services vs.
integrated has been previously described [8]. Comorbidity was calculated using the Adult Comorbidity Evaluation-27 (ACE-27) index [11]. The cardiovascular
comorbidities were collected as a part of the ACE-27. Some percentages may not sum to 100 due to rounding.
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nous 5-fluorouracil (with or without other chemother-
apy), in accordance with the FDA indication (Table 2).
Thirteen percent received bevacizumab with capecitabine
(with or without other chemotherapy).
Only 20% of those who received first-line bevacizumab
received it with irinotecan–19% with 5-fluorouracil, as
described in the pivotal phase III study, and 1% with
capecitabine (Table 2). Fifty-three percent received beva-
cizumab in combination with oxaliplatin. Eight percent
received bevacizumab with 5-fluorouracil alone; 5% with
capecitabine alone; and 14% with “other” agents. No
patients received first-line bevacizumab as a single agent.
Factors associated with bevacizumab use
Twenty-six percent of men received first-line bevacizu-
mab (Table 3). In the multivariable model (Figure 3),
men were significantly less likely to receive first-line bev-
acizumab than women (adjusted OR 0.55; 95% CI 0.32-
0.93; p = 0.026). Bevacizumab use declined with age:
first-line bevacizumab was used by 41% of those < 55
years of age, 32% of those 55-64 years of age, 30% of
those 65-74 years of age, and 16% for those ≥ 75 years of
age. Patients ≥ 75 years old were significantly less likely
to receive first-line bevacizumab than younger (< 55
years) patients (adjusted OR 0.13; 95% CI 0.04-0.46; p =
0.001). Patients in the Atlantic region were more likely to
receive bevacizumab than those in the West-Midwest
(adjusted OR 2.51; 95% CI 1.37-4.59; p = 0.003), and
patients in the South region also tended to receive
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Figure 2 Bevacizumab usage within 12 months of FDA approval for colorectal cancer. ^. ^This study followed patients until January, 2006,
but data in this figure is shown only until February 2005 as numbers of participants starting any first-line chemotherapy (denominator) within a
particular quarter diminishes over time due to the fixed-cohort effect. In the year following approval, the highest percentage of use was seen in
July, 2004 (12 of 25, 48%), a month after publication of the pivotal, phase III study which confirmed the drug’s efficacy in the first line as a part
of combination therapy.
Table 2 Drugs used in combination with bevacizumab*
N
(N = 110)
%
Use as indicated by FDA label
5-fluorouracil included in the regimen 82 75
5-fluorouracil not included in the regimen 15 14
Unable to determine 5-fluorouracil use 13 12
Chemotherapy give in combination with
bevacizumab
5-fluorouracil plus oxaliplatin 51 46
5-fluorouracil plus irinotecan 21 19
Capecitabine plus oxaliplatin 8 7
Capecitabine plus irinotecan 1 1
5-fluorouracil alone 9 8
Capecitabine alone 5 5
Other 15 14
*Some percentages may not sum to 100 due to rounding. FDA, Food and
Drug Administration.
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Characteristic* Received first-line
bevacizumab
(n = 110)
Unadjusted p-
value
#
%
Age (years) 0.007
<5 5 4 1
55-64 32
65-74 30
≥ 75 16
ACE-27 Comorbidity Index (score) 0.831
None (0) 29
Mild (1) 30
Moderate (2) 35
Severe (3) 34
Race 0.403
Non-white 28
White 33
Gender 0.005
Female 41
Male 26
Insurance 0.005
Private 41
Public 20
Medicare + supplemental 32
Veterans Administration 21
Missing 21
Health system 0.050
Fee-for-service 35
Integrated health system 25
Geographic region 0.003
West/Midwest 23
Southern 35
Atlantic 43
Annual household income 0.127
< $20,000/year 25
≥ $20,000/year 34
Missing 30
Diagnosis of metastatic disease 0.532
Stage IV at diagnosis 30
Recurrence 35
Did anyone mention that enrollment in a clinical trial might be an option for you? 0.152
Yes 38
No 28
Missing 35
How often do you read books, magazines or newspapers? 0.111
Often 35
Rarely 24
Missing 26
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Page 7 of 12bevacizumab more often than those in the West-Midwest
(adjusted OR 2.16; 95% CI 1.17-4.00; p = 0.014).
Patients’ race was not significantly associated with
receipt of bevacizumab, nor was insurance status. To
assess the effect of organization of care, apart from
insurance type, we substituted health system for
insurance in the adjusted analyses. No significant asso-
ciation was seen between health system type and receipt
of first-line bevacizumab, and none of the other associa-
tions were substantially altered. The relationship
between patients’ income and receipt of bevacizumab
was not significant.
Table 3 Percent of patients who received first-line bevacizumab by selected patient characteristics (Continued)
After talking with your doctors about chemotherapy, how likely did you think it was that chemotherapy
would have side-effects or complications?
0.133
Likely 33
Not likely 24
Missing 30
*The composition of health systems in the categorization of fee-for-services vs. integrated health systems has been previously described [8]. Comorbidity was
calculated using the Adult Comorbidity Evaluation-27 (ACE-27) index [11]. The cardiovascular comorbidities were collected as a part of the ACE-27.
#Unadjusted
p-values for aggregate variable effects (type 3 Wald statistics).
Less likely to receive
bevacizumab
More likely to receive
bevacizumab n=352
Figure 3 Sociodemographic and clinical factors associated with receipt of first-line bevacizumab: multivariable logistic regression
model results
#.
#n = 352. Three patients were excluded due to missing explanatory variables. Model results incorporate formal adjustments for
multiple imputations of missing data. OR’s and CI’s are plotted on a log scale. Comorbidity was calculated using the Adult Comorbidity
Evaluation-27 Scale. Abbreviations: OR, adjusted odds ratio; CI, confidence interval; ATL, Atlantic; SOU, Southern; WMW, West/Midwest. *P-values
for aggregate variable effects (type 3 Wald statistics) are listed next to each variable category in the left-hand column.
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ciated with receipt of first-line bevacizumab. Since cardio-
vascular comorbidity presents a potential contraindication,
we also examined the specific impact of cardiovascular
comorbidity on bevacizumab use. In the unadjusted analy-
sis, we found no statistically significant association
between bevacizumab use and the presence of cardiovas-
cular disease. Patients’ knowledge, belief, and attitudes
were also not statistically significantly associated with
receipt of bevacizumab (Table 3). However, due to miss-
ingness, these variables were not included in the final ana-
lytic model.
Discussion
Over the two years following approval of bevacizumab for
first-line treatment of advanced colorectal cancer, we
found that 31% of a nationally-representative sample of
treated patients received the agent as a component of their
care. Bevacizumab use showed an initial rapid uptake in
the first 6 months after FDA approval and then leveled off.
Seventy-five percent of patients received bevacizumab
with intravenous 5-fluorouracil (with or without other
chemotherapy), in accordance with the label. Only 19% of
patients received bevacizumab with irinotecan and 5-fluor-
ouracil, as described in the pivotal clinical trial which led
to FDA approval. Prior to this study, little was known
about the patterns of bevacizumab use soon after FDA
approval, and little was known about the factors associated
with early use. Registry studies for bevacizumab examined
post-marketing safety and efficacy,[5,6] but all enrolled
patients in those studies received bevacizumab; hence,
those studies could not address questions related to
dissemination.
The rapid increase noted in the first year was unprece-
dented for a cancer drug,[17] and was likely a conse-
quence of two factors. First, when it was approved, the
drug received a great deal of media attention, including
being called “revolutionary.”[18] This attention presum-
ably promoted initial uptake by oncologists. Second,
bevacizumab was the first anti-angiogenic agent to
demonstrate improvement in overall survival for colorec-
tal cancer-a potential paradigm shift in cancer treatment
that also may have stimulated an upsurge of initial inter-
est on the part of oncologists [19].
Why, despite the rapid rise, did early bevacizumab
uptake level off at less than one-third of eligible patients?
Our data suggest that clinicians may have restricted their
use to a sub-segment of potentially eligible patients. We
found that older age, even after adjusting for comorbid-
ity, was associated with less bevacizumab use. The mean
age of patients who received bevacizumab in our study
was 58.2 years, nearly identical to the mean age of 59.5
years in the pivotal phase III trial [1]. Early adopters of
the drug may have worried that its safety in elderly
patients was not adequately addressed by the trial design
and were hesitant to use the novel therapy in older
patients without post-approval data. Hence, they limited
use of the drug to patients who were similar to those
treated in the definitive clinical trial. Similar findings
have been noted among colorectal cancer patients eligible
for adjuvant chemotherapy: the elderly receive lower
doses and shorter duration of therapy than recom-
mended by trial data [20].
Men were less likely than women to receive bevacizu-
mab. It is unclear why gender played a role, especially
since prior studies investigating the impact of gender on
treatment of colorectal cancer have found no difference
[21,22]. Men are more likely than women to have subclini-
cal cardiovascular disease [23] and to be taking aspirin
[24]. In the phase III trial of bevacizumab, patients were
excluded if they had significant cardiovascular disease, reg-
ular aspirin use (> 325 mg per day), preexisting bleeding
disorders, or full-dose anticoagulation [1]. Although we
adjusted for cardiovascular comorbidity, our measures
may not have fully captured these specific conditions.
Clinicians might have been more hesitant to use the drug
in men with greater cardiovascular risk given the exclusion
criteria in the pivotal trial. To ensure that the gender effect
was not due to confounding by the largely male Veterans
Administration population we did a secondary analysis
excluding the Veterans Administration patients and found
no change in the association between gender and receipt
of bevacizumab.
The FDA approved bevacizumab in 2004 to be used in
combination with intravenous 5-fluorouracil-based che-
motherapy,[13] based on results of the pivotal phase III
study, which used bevacizumab in combination with irino-
tecan and 5-fluorouracil (IFL) [1]. Although the pivotal
trial was designed with IFL as the chemotherapy back-
bone, the label considered bevacizumab in combination
with any first-line 5-fluorouracil-containing regimen to be
on label. The relative flexibility that the FDA provided to
oncologists by labeling it for use in combination with any
5-fluorouracil-containing regimen might have been the
result of rising concern over excessive rates of treatment-
associated deaths with IFL [25,26]. Hence, oncologists
could use bevacizumab in combination with oxaliplatin
and still remain in accordance with the FDA indication.
Despite lack of evidence at the time for use with oxali-
platin, more than twice as many patients in our study
received bevacizumab with oxaliplatin than with irinote-
can. Due to the concern over treatment-associated deaths
with IFL, clinicians may have opted to use oxaliplatin-
based regimens with the assumption that the incremental
advantage of adding bevacizumab would be similar to IFL.
In fact, when evidence was subsequently published in
2008 for bevacizumab given in combination with 5-fluor-
ouracil and oxaliplatin (FOLFOX), no significant
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FOLFOX alone [27]. Additionally, some bevacizumab-
receiving patients in our study were not treated with first-
line 5-fluorouracil at all, thereby receiving off-label treat-
ment. A few bevacizumab-receiving patients were treated
with capecitabine, an approach that was not supported by
published evidence or FDA indication.
We observed a somewhat complex relationship between
the initial evidence supporting use of bevacizumab in
patients with advanced colorectal cancer and early pat-
terns of uptake. Clinicians were apparently guided by the
eligibility criteria of the trial, hesitating to treat older
patients or those at risk for cardiovascular compromise.
However, they chose to give the drug in combination with
chemotherapy regimens not supported by the FDA or
existing evidence at the time. Future studies of the disse-
mination of subsequently approved targeted agents will be
needed to determine whether these patterns were specific
to adoption of this new biologic agent or apply more
broadly to other biologic treatments for cancer. We also
saw no association with patient preferences or beliefs. Our
findings thus suggest that oncologists, not patients, were
the primary decision-makers about whether to include
bevacizumab for patients treated with chemotherapy.
Our analysis revealed regional disparities, with patients
living in the Atlantic region being more likely than those
in other regions to receive bevacizumab. Regional variation
has been well-described in relation to delivery of both
surgery and chemotherapy for various cancers [28-33].
Our findings of regional variation are unlikely the result
of differential reimbursement for bevacizumab since
the US Centers for Medicare & Medicaid Services (CMS)
approved coverage for bevacizumab retroactive to the
FDA approval date. Furthermore, the regional variation is
unlikely to have been the result of formulary availability
within each health system, since in the US anticancer
drugs are generally available on formulary at the time of
FDA approval. In their review of 59 anticancer drugs
(including bevacizumab), Mason et al. found that 100% of
drugs were covered by CMS and the Veterans Administra-
tion health system from the time of FDA approval [34].
Additionally, at least in the Veterans Administration
health system, bevacizumab was available prior to formu-
lary listing but after FDA approval via non-formulary
request (personal communication, Geraci M, 2010).
Our study has several limitations. While we assessed
patient preferences and beliefs, we could not assess pre-
ferences specific to bevacizumab. Our cohort is a small
sub-sample drawn from a relatively large cohort, though
it is large enough to support robust analysis, and Can-
CORS enrollees are representative of patients included
in the SEER cancer registry [9]. Additionally, longitudi-
nal follow-up of our cohort was short.
Conclusions
We found a rapid uptake of bevacizumab after FDA
approval, though only a third of eligible patients received
the drug. Use of bevacizumab in practice differed from
that described in clinical trials leading to FDA approval.
Dissemination of novel agents might be improved
through comparative effectiveness research measuring
the benefits and safety of treatments through post-mar-
keting (phase IV) studies that track the dissemination of
new therapies and their associated outcomes.
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